[1] |
|
[2] |
FERENCE B A, GINSBERG H N, GRAHAM I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,epidemiologic,and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017, 38(32):2459-2472. DOI: 10.1093/eurheartj/ehx144.
|
[3] |
国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京:科学出版社,2022.
|
[4] |
SONG P K, MAN Q Q, LI H, et al. Trends in lipids level and dyslipidemia among Chinese adults,2002-2015[J]. Biomed Environ Sci, 2019, 32(8):559-570. DOI: 10.3967/bes2019.074.
|
[5] |
YANG W Y, XIAO J Z, YANG Z J, et al. Serum lipids and lipoproteins in Chinese men and women[J]. Circulation, 2012, 125(18):2212-2221. DOI: 10.1161/CIRCULATIONAHA.111.065904.
|
[6] |
ZHANG M, DENG Q, WANG L H, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults:a nationally representative survey of 163,641 adults[J]. Int J Cardiol, 2018, 260:196-203. DOI: 10.1016/j.ijcard.2017.12.069.
|
[7] |
NCD Risk Factor Collaboration(NCD-RISC). Repositioning of the global epicentre of non-optimal cholesterol[J]. Nature, 2020, 582(7810):73-77. DOI: 10.1038/s41586-020-2338-1.
|
[8] |
DING W Q, CHENG H, YAN Y K, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing,China[J]. J Epidemiol, 2016, 26(12):637-645. DOI: 10.2188/jea.JE20140252.
|
[9] |
国家卫生健康委员会疾病预防控制局.中国居民营养与慢性病状况报告2020[M].北京:人民卫生出版社,2020.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
LU Y, ZHANG H B, LU J P, et al. Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China[J]. JAMA Netw Open, 2021, 4(9):e2127573. DOI: 10.1001/jamanetworkopen.2021.27573.
|
[16] |
LI S, LIU H H, GUO Y L, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement:a population-based study[J]. Lancet Reg Health West Pac, 2021, 17:100286. DOI: 10.1016/j.lanwpc.2021.100286.
|
[17] |
COLLABORATION C T T, BAIGENT C, BLACKWELL L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753):1670-1681. DOI: 10.1016/S0140-6736(10)61350-5.
|
[18] |
Cholesterol Treatment Trialists' Collaborators, MIHAYLOVA B, EMBERSON J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841):581-590. DOI: 10.1016/S0140-6736(12)60367-5.
|
[19] |
FERENCE B A, BHATT D L, CATAPANO A L, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease[J]. JAMA, 2019, 322(14):1381-1391. DOI: 10.1001/jama.2019.14120.
|
[20] |
FERENCE B A, GRAHAM I, TOKGOZOGLU L, et al. Reprint of:impact of lipids on cardiovascular health:JACC health promotion series[J]. J Am Coll Cardiol, 2018, 72(23 Pt B):2980-2995. DOI: 10.1016/j.jacc.2018.10.021.
|
[21] |
中国血脂管理指南(2023年)中国血脂管理指南修订联合专家委员会.中国血脂管理指南(2023)[J].中国循环杂志,2023,38(3):237-269.
|
[22] |
姚文山. 国家基本公共卫生服务规范(第三版)[M]. 北京:中国原子能出版社,2017:1-204.
|
[23] |
SCHWALM JD, MCCREADY T, LOPEZ-JARAMILLO P, et al. A community-based comprehensive intervention to reduce cardio-vascular risk in hypertension(HOPE 4):a cluster-randomised controlled trial[J]. Lancet, 2019, 394(10205):1231-1242. DOI: 10.1016/S0140-6736(19)31949-X.
|
[24] |
SUN Y, MU J, WANG DW, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China:an open,cluster randomised trial[J]. Lancet, 2022, 399(10339):1964-1975. DOI: 10.1016/S0140-6736(22)00325-7.
|